In a deal potentially worth more than US$1.1 B, MacroGenics has formed a collaboration with Gilead Sciences to develop and commercialise bispecific antibodies directed at up to four undisclosed targets using its DART™ (dual-affinity re-targeting) technology platform. Gilead will fully fund research activities for all four programmes and will receive global rights to three of these programmes. MacroGenics retain rights outside of North America, Europe, Australia and New Zealand for one programme. The company’s other DART collaborators include Boehringer Ingelheim, Pfizer and Les Laboratoires Servier.